Opdivo Qvantig vs Pembrolizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Pembrolizumab
Marketed by Merck & Co.
NCT02142738 · Phase 3 · completed
The trial randomized 305 participants to pembrolizumab or active platinum-based chemotherapy, but treatment was open-label rather than double-blinded. Its radiographically assessed primary endpoint, 6-month progression-free survival, was met: 62.1% with pembrolizumab versus 50.3% with chemotherapy, with p<0.001 and a hazard ratio of 0.50 (95% CI 0.37–0.68).
Next expected readout: November 2026 · NCT06545331 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) Rate at Month 6: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2) (met)
Result source: NCT02142738
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Opdivo Qvantig | Pembrolizumab |
|---|---|---|
| PFS, median | —Not reported | 8.8 vs 4.9+3.9 vs placeboNCT0257868017 other results
|
| OS, median | —Not reported | 15.9 vs 11.3+4.6 vs placeboNCT0277543515 other results
|
| ORR | —Not reported | 47.6% vs 18.9%+28.7 vs placeboNCT0257868014 other results
|
| Duration of response, median | —Not reported | 11.2 vs 7.8+3.4 vs placeboNCT025786808 other results
|
PFS, median
- Opdivo Qvantig
- —Not reported
- Pembrolizumab
- 8.8 vs 4.9+3.9 vs placeboNCT02578680
17 other results
- 6.4 vs 4.8 NCT02775435
- 5.6 vs 5.5 NCT03515837
- 5.6 vs 4.2 NCT03976375
- 4 vs 2.5 NCT02864394
- 3.3 vs 3 NCT02864394
- 7.1 NCT03976323
- 8.3 NCT03976323
- 6.5 vs 6.4 NCT02220894
- 6.2 vs 6.7 NCT02220894
- 5.4 vs 6.6 NCT02220894
- 2.5 vs 2.4 NCT04165096
- 4.5 vs 5.2 NCT03971474
- 29 NCT03631784
- 45.3 NCT03631784
- 7 NCT05077709
- 2.6 NCT02955758
- 4.4 NCT02733159
OS, median
- Opdivo Qvantig
- —Not reported
- Pembrolizumab
- 15.9 vs 11.3+4.6 vs placeboNCT02775435
15 other results
- 15.9 vs 14.7 NCT03515837
- 20 vs 12.2 NCT02220894
- 18 vs 13 NCT02220894
- 16.4 vs 12.1 NCT02220894
- 11.3 vs 12 NCT03976375
- 12.3 vs 10.9 NCT02864394
- 12.9 vs 10.6 NCT02864394
- 20.7 NCT03976323
- 23 NCT03976323
- 14.5 vs 11.6 NCT03971474
- 35.6 NCT03631784
- 56.7 NCT03631784
- 9.8 NCT02733159
- 22.3 NCT05077709
- 13.3 NCT02955758
ORR
- Opdivo Qvantig
- —Not reported
- Pembrolizumab
- 47.6% vs 18.9%+28.7 vs placeboNCT02578680
14 other results
- 57.9% vs 38.4% NCT02775435
- 29% vs 27.1% NCT03515837
- 39.1% vs 32% NCT02220894
- 33.2% vs 28.9% NCT02220894
- 27.2% vs 26.5% NCT02220894
- 44.8% vs 27.8% NCT02142738
- 22.7% vs 14.3% NCT03976375
- 22.7% vs 12.5% NCT03976375
- 28.1% vs 7.1% NCT02864394
- 20.7% vs 5.7% NCT02864394
- 5.4% vs 11.1% NCT04165096
- 71.4% NCT03631784
- 75.5% NCT03631784
- 22% vs 28% NCT03971474
Duration of response, median
- Opdivo Qvantig
- —Not reported
- Pembrolizumab
- 11.2 vs 7.8+3.4 vs placeboNCT02578680
8 other results
- 7.7 vs 4.8 NCT02775435
- 6.3 vs 5.6 NCT03515837
- 6.9 vs 6.8 NCT03976375
- 16.6 vs 6.4 NCT02864394
- 16.6 vs 6.3 NCT02864394
- 12.9 vs 5.6 NCT03971474
- 14.6 NCT02733159
- 12.5 NCT05077709
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Opdivo Qvantig: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Opdivo Qvantig: 0 of 4 rows · Pembrolizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Pembrolizumab |
|---|---|
| Dropout rate | n/a: no completion milestonePembrolizumaba NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 48 more results—Pembrolizumab First Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —Pembrolizumab Second Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 54%10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 58.8%2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 n/a: no completion milestonePembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination —Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination n/a: no completion milestone NCT02775435 · Phase 3 · combination n/a: no completion milestone NCT02220894 · Phase 3 n/a: no completion milestone NCT02504372 · Phase 3 89.3%200 mg IV Q3W NCT03715205 · Phase 4 · registry result, not featured evidence —Pembrolizumab (First Course) + Ola NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (First Course) + Pem NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (Second Course) + Ol NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (Second Course) + Pe NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Olaparib (Maintena NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Pemetrexed (Mainte NCT03976323 · Phase 3 · registry result, not featured evidence · combination 33%Pembrolizumab + Pemetrexed + Plati NCT03976323 · Phase 3 · registry result, not featured evidence · combination 0%Arm 1 Stereotactic Body Radiation NCT03867175 · Phase 3 · registry result, not featured evidence · combination 0%Arm 2 Pembrolizumab Only NCT03867175 · Phase 3 · registry result, not featured evidence —Pembrolizumab + Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestonePembrolizumab+Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT03515837 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT03875092 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT03950674 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT02864394 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT03850444 · Phase 3 · registry result, not featured evidence 2.5% NCT03634241 · Phase 2 · registry result, not featured evidence 90.5%Arm B (SCCHN) NCT05077709 · Phase 2 · registry result, not featured evidence · combination 60%Arm C (mUBC) NCT05077709 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone800 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone200 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestonePembrolizumab + Lenvatinib NCT03516981 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestonePembrolizumab + Quavonlimab NCT03516981 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone NCT04165096 · Phase 2 · registry result, not featured evidence · combination 0%Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence 50%Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence 80.7%1st Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 89.2%2nd Line HNSCC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 94.4%2nd Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 0% NCT02955758 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePembrolizumab + cCRT + Paclitaxel NCT03631784 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestonePembrolizumab + cCRT + Pemetrexed NCT03631784 · Phase 2 · registry result, not featured evidence · combination 3.2% NCT02733159 · Phase 2 · registry result, not featured evidence 87.7% NCT03004183 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT03971474 · Phase 2 · registry result, not featured evidence · combination 86.4% NCT03087760 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 8.4%Pembrolizumaba NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 48 more results—Pembrolizumab First Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —Pembrolizumab Second Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 4.9%10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 6.7%2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination —Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination 11.5% NCT02775435 · Phase 3 · combination 19.9% NCT02220894 · Phase 3 — NCT02504372 · Phase 3 —200 mg IV Q3W NCT03715205 · Phase 4 · registry result, not featured evidence —Pembrolizumab (First Course) + Ola NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (First Course) + Pem NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (Second Course) + Ol NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (Second Course) + Pe NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Olaparib (Maintena NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Pemetrexed (Mainte NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Pemetrexed + Plati NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Arm 1 Stereotactic Body Radiation NCT03867175 · Phase 3 · registry result, not featured evidence · combination —Arm 2 Pembrolizumab Only NCT03867175 · Phase 3 · registry result, not featured evidence —Pembrolizumab + Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab+Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination — NCT03515837 · Phase 3 · registry result, not featured evidence · combination 3.1% NCT03875092 · Phase 3 · registry result, not featured evidence · combination — NCT03950674 · Phase 3 · registry result, not featured evidence · combination — NCT02864394 · Phase 3 · registry result, not featured evidence 12.5% NCT03850444 · Phase 3 · registry result, not featured evidence — NCT03634241 · Phase 2 · registry result, not featured evidence —Arm B (SCCHN) NCT05077709 · Phase 2 · registry result, not featured evidence · combination —Arm C (mUBC) NCT05077709 · Phase 2 · registry result, not featured evidence · combination —800 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination —200 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination —Pembrolizumab + Lenvatinib NCT03516981 · Phase 2 · registry result, not featured evidence · combination —Pembrolizumab + Quavonlimab NCT03516981 · Phase 2 · registry result, not featured evidence · combination — NCT04165096 · Phase 2 · registry result, not featured evidence · combination —Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence —Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence —1st Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination —2nd Line HNSCC NCT03625323 · Phase 2 · registry result, not featured evidence · combination —2nd Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination — NCT02955758 · Phase 2 · registry result, not featured evidence —Pembrolizumab + cCRT + Paclitaxel NCT03631784 · Phase 2 · registry result, not featured evidence · combination —Pembrolizumab + cCRT + Pemetrexed NCT03631784 · Phase 2 · registry result, not featured evidence · combination 1.6% NCT02733159 · Phase 2 · registry result, not featured evidence 12.3% NCT03004183 · Phase 2 · registry result, not featured evidence 11.6% NCT03971474 · Phase 2 · registry result, not featured evidence · combination — NCT03087760 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —Pembrolizumaba NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 48 more results51.3%Pembrolizumab First Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 16.7%Pembrolizumab Second Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 38.8%10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 36.6%2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 57.5%Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination 22.2%Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination 46% NCT02775435 · Phase 3 · combination 41% NCT02220894 · Phase 3 24.5% NCT02504372 · Phase 3 20.7%200 mg IV Q3W NCT03715205 · Phase 4 · registry result, not featured evidence 35%Pembrolizumab (First Course) + Ola NCT03976323 · Phase 3 · registry result, not featured evidence · combination 37.7%Pembrolizumab (First Course) + Pem NCT03976323 · Phase 3 · registry result, not featured evidence · combination 0%Pembrolizumab (Second Course) + Ol NCT03976323 · Phase 3 · registry result, not featured evidence · combination 7.7%Pembrolizumab (Second Course) + Pe NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Olaparib (Maintena NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Pemetrexed (Mainte NCT03976323 · Phase 3 · registry result, not featured evidence · combination 23.4%Pembrolizumab + Pemetrexed + Plati NCT03976323 · Phase 3 · registry result, not featured evidence · combination 50%Arm 1 Stereotactic Body Radiation NCT03867175 · Phase 3 · registry result, not featured evidence · combination 100%Arm 2 Pembrolizumab Only NCT03867175 · Phase 3 · registry result, not featured evidence 54.7%Pembrolizumab + Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab+Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination 35.1% NCT03515837 · Phase 3 · registry result, not featured evidence · combination 53.8% NCT03875092 · Phase 3 · registry result, not featured evidence · combination 36% NCT03950674 · Phase 3 · registry result, not featured evidence · combination 36.2% NCT02864394 · Phase 3 · registry result, not featured evidence 32.8% NCT03850444 · Phase 3 · registry result, not featured evidence 7.5% NCT03634241 · Phase 2 · registry result, not featured evidence 9.5%Arm B (SCCHN) NCT05077709 · Phase 2 · registry result, not featured evidence · combination 20%Arm C (mUBC) NCT05077709 · Phase 2 · registry result, not featured evidence · combination 60.8%800 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination 46.7%200 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination 52.5%Pembrolizumab + Lenvatinib NCT03516981 · Phase 2 · registry result, not featured evidence · combination 47.6%Pembrolizumab + Quavonlimab NCT03516981 · Phase 2 · registry result, not featured evidence · combination 37.8% NCT04165096 · Phase 2 · registry result, not featured evidence · combination 10.8%Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence 20%Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence 47.4%1st Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 54.1%2nd Line HNSCC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 25%2nd Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 36% NCT02955758 · Phase 2 · registry result, not featured evidence 58.9%Pembrolizumab + cCRT + Paclitaxel NCT03631784 · Phase 2 · registry result, not featured evidence · combination 45.1%Pembrolizumab + cCRT + Pemetrexed NCT03631784 · Phase 2 · registry result, not featured evidence · combination 85% NCT02733159 · Phase 2 · registry result, not featured evidence 51.8% NCT03004183 · Phase 2 · registry result, not featured evidence 40.6% NCT03971474 · Phase 2 · registry result, not featured evidence · combination 45.5% NCT03087760 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a diarrhoea 26.6% dyspnoea 26.6% fatigue 24% NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 42 more resultsupper respiratory tract infection 33.3% constipation 16.7% decreased appetite 16.7% NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 10 mg/kg fatigue 25.7% decreased appetite 23.3% dyspnoea 23% NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 2 mg/kg decreased appetite 30.7% fatigue 30.1% nausea 25.7% NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 nausea 57.3% (placebo 51%) anaemia 45.9% (placebo 45%) fatigue 42.7% (placebo 39.6%) NCT02578680 · Phase 3 · combination abdominal pain 22.2% (placebo 6.4%) cough 22.2% (placebo 30.7%) diarrhoea 22.2% (placebo 20.3%) NCT02578680 · Phase 3 · combination anaemia 53.2% (placebo 49.6%) alopecia 46% (placebo 37.5%) nausea 36.3% (placebo 32.1%) NCT02775435 · Phase 3 · combination weight increased 22.8% (placebo 28.9%) pruritus 21.6% (placebo 12.7%) hypothyroidism 20.7% (placebo 4.6%) NCT02504372 · Phase 3 200 mg IV Q3W hypothyroidism 17.3% anaemia 12.7% constipation 11.3% NCT03715205 · Phase 4 · registry result, not featured evidence anaemia 36.2% nausea 24% fatigue 17.2% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anaemia 37.7% nausea 19% aspartate aminotransferase increased 16.6% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anaemia 14.3% covid-19 14.3% headache 14.3% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anaemia 15.4% cough 15.4% productive cough 15.4% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anaemia 38.4% nausea 30.9% neutropenia 23.4% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anemia 75% cough 75% abdominal pain 50% NCT03867175 · Phase 3 · registry result, not featured evidence · combination alanine aminotransferase increased 100% alkaline phosphatase increased 100% aspartate aminotransferase increased 100% NCT03867175 · Phase 3 · registry result, not featured evidence hypertension 41.4% diarrhoea 40.9% hypothyroidism 35.4% NCT03976375 · Phase 3 · registry result, not featured evidence · combination anaemia 40.4% (placebo 44.7%) nausea 39.2% (placebo 43.5%) neutrophil count decreased 36.7% (placebo 45.9%) NCT03515837 · Phase 3 · registry result, not featured evidence · combination alopecia 78.5% white blood cell count decreased 78.5% neutrophil count decreased 76.9% NCT03875092 · Phase 3 · registry result, not featured evidence · combination nausea 72% (placebo 53.3%) constipation 64% (placebo 73.3%) decreased appetite 56% (placebo 60%) NCT03950674 · Phase 3 · registry result, not featured evidence · combination anaemia 33.3% aspartate aminotransferase increased 21.6% cough 21.6% NCT02864394 · Phase 3 · registry result, not featured evidence fatigue 45% investigations 25% alanine aminotransferase increased 20% NCT03634241 · Phase 2 · registry result, not featured evidence anaemia 42.9% diarrhoea 33.3% fatigue 28.6% NCT05077709 · Phase 2 · registry result, not featured evidence · combination asthenia 40% blood creatinine increased 40% blood urea increased 40% NCT05077709 · Phase 2 · registry result, not featured evidence · combination 800 mg diarrhoea 29.4% fatigue 21.6% alanine aminotransferase increased 19.6% NCT03516981 · Phase 2 · registry result, not featured evidence · combination 200 mg pyrexia 23.3% constipation 20% decreased appetite 20% NCT03516981 · Phase 2 · registry result, not featured evidence · combination hypertension 52.5% diarrhoea 45% hypothyroidism 36.3% NCT03516981 · Phase 2 · registry result, not featured evidence · combination pruritus 29.3% cough 22% fatigue 20.7% NCT03516981 · Phase 2 · registry result, not featured evidence · combination fatigue 29.7% pruritus 29.7% nausea 24.3% NCT04165096 · Phase 2 · registry result, not featured evidence · combination anorexia 40% gastrointestinal disorders - other, specify 40% hypertension 40% NCT02681549 · Phase 2 · registry result, not featured evidence asthenia 34.2% dyspnoea 34.2% cough 29.8% NCT03625323 · Phase 2 · registry result, not featured evidence · combination asthenia 21.6% anaemia 18.9% cough 18.9% NCT03625323 · Phase 2 · registry result, not featured evidence · combination decreased appetite 36.1% dyspnoea 36.1% cough 30.6% NCT03625323 · Phase 2 · registry result, not featured evidence · combination nausea 24% decreased appetite 20% worsening abdominal pain 20% NCT02955758 · Phase 2 · registry result, not featured evidence anaemia 39.3% fatigue 34.8% alopecia 31.3% NCT03631784 · Phase 2 · registry result, not featured evidence · combination nausea 52% asthenia 40.2% anaemia 32.4% NCT03631784 · Phase 2 · registry result, not featured evidence · combination fatigue 21.4% nausea 12.5% back pain 10.7% NCT03004183 · Phase 2 · registry result, not featured evidence fatigue 56.5% hypoalbuminemia 44.9% hyponatremia 39.1% NCT03971474 · Phase 2 · registry result, not featured evidence · combination esophagitis 36.4% fatigue 36.4% hypothyroidism 22.7% NCT03087760 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 42 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pembrolizumab
show 12 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 10 more results
show 9 more results
show 6 more results
show 3 more results
show 7 more results
+ 48 further endpoints in the CSV export.
Urothelial Carcinoma
Shared mechanism: PD-1 · full Urothelial Carcinoma pipeline
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Pembrolizumab
Marketed by Merck & Co.
NCT04223856 · Phase 3 · active, not recruiting
The trial was randomized and actively controlled, with 442 participants assigned to enfortumab vedotin plus pembrolizumab and 444 to chemotherapy, but treatment assignment was not blinded. Both primary endpoints were met in favor of the combination: independently reviewed progression-free survival and overall survival were significantly improved, but the open-label design and lack of a reported power calculation in the provided record support a moderate grade rather than a strong one.
Next expected readout: December 2026 · NCT04164082 (registry estimate)
Reported efficacy
Pembro Combo vs Chemo: Progression-free Survival (PFS) Using Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) (Up to approximately 42 months); Pembro Combo vs Chemo: Overall Survival (OS) (Up to approximately 42 months); Pembro vs Chemo: OS in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10% (Up to approximately 42 months); Pembro vs Chemo: OS (Up to approximately 42 months): Pembrolizumab plus chemotherapy vs chemotherapy: PFS median 8.3 vs 7.1 months (HR 0.78, 95% CI 0.65 to 0.93; p=0.0033 against a boundary of 0.0019); OS median 17.0 vs 14.3 months (HR 0.86, 95% CI 0.72 to 1.02; p=0.0407 against a boundary of 0.0142). Pembrolizumab monotherapy OS comparisons were exploratory after the hierarchy stopped (KEYNOTE-361, Lancet Oncol 2021). (missed)
Result source: NCT02853305
Results for Urothelial Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opdivo Qvantig: no structured comparison results are available for Urothelial Carcinoma.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pembrolizumab
show 3 more results
show 3 more results
show 3 more results
show 2 more results
show 3 more results
Available safety results
Pembrolizumab
| Dropout rate | 25%Experimental: Expansion 1 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination show 15 more results0%Experimental: Expansion 2 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 4.8%Experimental: Expansion 3 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 0%Experimental: Safety Lead In NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 57.1%20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | —Experimental: Expansion 1 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination show 15 more results—Experimental: Expansion 2 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination —Experimental: Expansion 3 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination —Experimental: Safety Lead In NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination —300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 1.6%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 66.7%Experimental: Expansion 1 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination show 15 more results60%Experimental: Expansion 2 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 35%Experimental: Expansion 3 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 16.7%Experimental: Safety Lead In NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 45%300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 51%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 40%50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 38.2%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 35.7%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 37.5%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 14.3%20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | decreased appetite 50% alanine aminotransferase increased 33.3% diarrhea 33.3% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination show 12 more resultsanaemia 80% dizziness 80% fatigue 80% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination dizziness 45% decreased appetite 30% dyspnea 30% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination abdominal pain 66.7% blood alkaline phosphatase increased 66.7% fatigue 66.7% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 300 mg BID + 200 mg Q3W fatigue 65% nausea 55% vomiting 50% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 50% back pain 38.9% diarrhoea 38.9% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 48.4% nausea 30.1% cough 26.2% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50 mg BID + 200 mg Q3W fatigue 65% arthralgia 45% nausea 45% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 25 mg BID + 200 mg Q3W arthralgia 100% constipation 75% cough 75% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg diarrhoea 25.2% constipation 23.6% fatigue 23.6% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 75 mg aspartate aminotransferase increased 21.4% back pain 21.4% fatigue 21.4% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 50 mg fatigue 37.5% diarrhoea 25% decreased appetite 18.8% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 20 mg/kg hypertension 28.6% anemia 14.3% arthralgia 14.3% NCT03236935 · Phase 1 · registry result, not featured evidence |
Hepatocellular Carcinoma
Shared mechanism: PD-1 · full Hepatocellular Carcinoma pipeline
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Pembrolizumab
Marketed by Merck & Co.
NCT03062358 · Phase 3 · completed
Patients were randomly assigned 2:1 to pembrolizumab or placebo, with patients and investigators blinded. Overall survival, the primary endpoint, was significantly longer with pembrolizumab (hazard ratio 0.79, 95% CI 0.63 to 0.99, one-sided p=0.0180). The protocol reports a power calculation for overall survival and 453 patients were enrolled against a planned 450.
Next expected readout: December 2026 · NCT03419481 (registry estimate)
Reported efficacy
Overall Survival (OS) (Up to approximately 4 years): Overall Survival (OS) (Up to approximately 4 years): Pembrolizumab + BSC 14.6 Months (95% CI 12.6 to 18) | Placebo + BSC 13 Months (95% CI 10.5 to 15.1) (met)
Result source: NCT03062358
Results for Hepatocellular Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opdivo Qvantig: no structured comparison results are available for Hepatocellular Carcinoma.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Available safety results
Pembrolizumab
| Dropout rate | n/a: no completion milestone300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 4 more resultsn/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | —300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 4 more results—100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 45%300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 4 more results50%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 51%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 40%50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 300 mg BID + 200 mg Q3W fatigue 65% nausea 55% vomiting 50% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 4 more results100 mg BID + 200 mg Q3W fatigue 50% back pain 38.9% diarrhoea 38.9% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 48.4% nausea 30.1% cough 26.2% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50 mg BID + 200 mg Q3W fatigue 65% arthralgia 45% nausea 45% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 25 mg BID + 200 mg Q3W arthralgia 100% constipation 75% cough 75% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination |
Gastric Cancer
Shared mechanism: PD-1 · full Gastric Cancer pipeline
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Pembrolizumab
Marketed by Merck & Co.
NCT03615326 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled phase 3 trial; 698 participants were randomized in its main cohort, more than the approximately 692 its published sample-size calculation required. Both primary endpoints were met: progression-free survival by blinded central review (hazard ratio 0.73) and overall survival (hazard ratio 0.80) were significantly better with pembrolizumab.
Next expected readout: December 2026 · NCT05041153 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Gastric Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opdivo Qvantig: no structured comparison results are available for Gastric Cancer.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pembrolizumab
show 11 more results
show 14 more results
show 15 more results
show 9 more results
show 5 more results
show 3 more results
show 3 more results
Available safety results
Pembrolizumab
| Dropout rate | n/a: no completion milestoneCohort A: Triple Negative Breast C NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 27 more resultsn/a: no completion milestoneCohort B: Ovarian Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort C: Gastric Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort D1: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort D2: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneCohort E: Glioblastoma Multiforma NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort F: Biliary Tract Cancer (Le NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort G: Pancreatic Cancer (Lenva NCT03797326 · Phase 2 · registry result, not featured evidence · combination 25%Experimental: Expansion 1 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 0%Experimental: Expansion 2 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 4.8%Experimental: Expansion 3 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 0%Experimental: Safety Lead In NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1.6 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1.6 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | —Cohort A: Triple Negative Breast C NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 27 more results—Cohort B: Ovarian Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Gastric Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort D1: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort D2: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence —Cohort E: Glioblastoma Multiforma NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort F: Biliary Tract Cancer (Le NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort G: Pancreatic Cancer (Lenva NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Experimental: Expansion 1 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination —Experimental: Expansion 2 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination —Experimental: Expansion 3 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination —Experimental: Safety Lead In NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination —300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 1.6%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination 50%2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination 66.7%1.6 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination 0%1.6 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 51.6%Cohort A: Triple Negative Breast C NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 27 more results61.3%Cohort B: Ovarian Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination 57.6%Cohort C: Gastric Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination 52.4%Cohort D1: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence · combination 40%Cohort D2: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence 29.7%Cohort E: Glioblastoma Multiforma NCT03797326 · Phase 2 · registry result, not featured evidence · combination 60.8%Cohort F: Biliary Tract Cancer (Le NCT03797326 · Phase 2 · registry result, not featured evidence · combination 47.6%Cohort G: Pancreatic Cancer (Lenva NCT03797326 · Phase 2 · registry result, not featured evidence · combination 66.7%Experimental: Expansion 1 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 60%Experimental: Expansion 2 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 35%Experimental: Expansion 3 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 16.7%Experimental: Safety Lead In NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 45%300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 51%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 40%50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 38.2%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 35.7%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 37.5%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —1.6 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —1.6 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | hypertension 51.6% diarrhoea 45.2% hypothyroidism 45.2% NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 19 more resultshypertension 67.7% diarrhoea 61.3% decreased appetite 48.4% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 37.4% nausea 31.3% asthenia 30.3% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 56.2% diarrhoea 44.8% decreased appetite 43.8% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 56.7% diarrhoea 53.3% dysphonia 40% NCT03797326 · Phase 2 · registry result, not featured evidence hypertension 50.5% asthenia 28.7% hypothyroidism 27.7% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 56.9% diarrhoea 41.2% fatigue 39.2% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 53.4% nausea 35.9% decreased appetite 32% NCT03797326 · Phase 2 · registry result, not featured evidence · combination decreased appetite 50% alanine aminotransferase increased 33.3% diarrhea 33.3% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination anaemia 80% dizziness 80% fatigue 80% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination dizziness 45% decreased appetite 30% dyspnea 30% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination abdominal pain 66.7% blood alkaline phosphatase increased 66.7% fatigue 66.7% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 300 mg BID + 200 mg Q3W fatigue 65% nausea 55% vomiting 50% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 50% back pain 38.9% diarrhoea 38.9% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 48.4% nausea 30.1% cough 26.2% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50 mg BID + 200 mg Q3W fatigue 65% arthralgia 45% nausea 45% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 25 mg BID + 200 mg Q3W arthralgia 100% constipation 75% cough 75% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg diarrhoea 25.2% constipation 23.6% fatigue 23.6% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 75 mg aspartate aminotransferase increased 21.4% back pain 21.4% fatigue 21.4% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 50 mg fatigue 37.5% diarrhoea 25% decreased appetite 18.8% NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
Melanoma
Shared mechanism: PD-1 · full Melanoma pipeline
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Pembrolizumab
Marketed by Merck & Co.
NCT01866319 · Phase 3 · completed
The trial randomized 834 participants to two pembrolizumab schedules or active-control ipilimumab, with progression assessed by blinded independent radiology review and statistically significant improvements in progression-free survival and overall survival for both pembrolizumab schedules versus ipilimumab. However, treatment assignment was open-label rather than double-blinded, so the evidence is rated moderate despite the objective clinical endpoints and favorable results.
Next expected readout: December 2026 · NCT02644369 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Melanoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opdivo Qvantig: no structured comparison results are available for Melanoma.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pembrolizumab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 16 more results
show 7 more results
show 7 more results
show 19 more results
show 12 more results
show 18 more results
show 6 more results
show 1 more result
+ 7 further endpoints in the CSV export.
Available safety results
Pembrolizumab
| Dropout rate | 89.3%200 mg IV Q3W NCT03715205 · Phase 4 · registry result, not featured evidence show 59 more results0%Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence 50%Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence 0%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 0%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 66.7%3 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase 1: Lung Targets + MK-3475 / NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase 1: Non-Lung Target + MK-3475 NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination 0%30 Gy over 5 fractions NCT02858869 · Phase 1 · registry result, not featured evidence · combination 0%27 Gy over 3 fractions NCT02858869 · Phase 1 · registry result, not featured evidence · combination 0%18-21 Gy in one fraction NCT02858869 · Phase 1 · registry result, not featured evidence · combination 100%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 99.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 96.5%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 85.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 0%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 57.1%20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence 92.3%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 92.5%10 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 91.6%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 93.2%10 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 100%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 100%3 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 89%2 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 90.2%2 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence 100%1 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 100%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence 66.7%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence 100%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | —200 mg IV Q3W NCT03715205 · Phase 4 · registry result, not featured evidence show 59 more results—Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence —Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —3 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —Phase 1: Lung Targets + MK-3475 / NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination —Phase 1: Non-Lung Target + MK-3475 NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination —30 Gy over 5 fractions NCT02858869 · Phase 1 · registry result, not featured evidence · combination —27 Gy over 3 fractions NCT02858869 · Phase 1 · registry result, not featured evidence · combination —18-21 Gy in one fraction NCT02858869 · Phase 1 · registry result, not featured evidence · combination —3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence —3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence —280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination —20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence 12%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 15.3%10 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 10.3%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 16.9%10 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 16.7%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 66.7%3 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 9.1%2 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 11.5%2 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence 25%1 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 25%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence 33.3%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence 66.7%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 20.7%200 mg IV Q3W NCT03715205 · Phase 4 · registry result, not featured evidence show 59 more results10.8%Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence 20%Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence 22.2%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 57.1%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 55.6%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 43.4%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 45.3%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 36.8%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 66.7%3 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 45%300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 51%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 40%50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50%Phase 1: Lung Targets + MK-3475 / NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination 20%Phase 1: Non-Lung Target + MK-3475 NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination 33.3%30 Gy over 5 fractions NCT02858869 · Phase 1 · registry result, not featured evidence · combination 41.7%27 Gy over 3 fractions NCT02858869 · Phase 1 · registry result, not featured evidence · combination 14.3%18-21 Gy in one fraction NCT02858869 · Phase 1 · registry result, not featured evidence · combination 40%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence 60%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 51.3%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence 47.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 56.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 55.6%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 66.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 66.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 16.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 57.1%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 20%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 40%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence 0%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 75%0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 14.3%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 66.7%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 100%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 14.3%20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence 43.9%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 41.2%10 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 42.6%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 41.5%10 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 30%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 33.3%3 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 42.6%2 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 55.7%2 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence 25%1 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 0%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence 66.7%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence 33.3%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 200 mg IV Q3W hypothyroidism 17.3% anaemia 12.7% constipation 11.3% NCT03715205 · Phase 4 · registry result, not featured evidence show 56 more resultsanorexia 40% gastrointestinal disorders - other, specify 40% hypertension 40% NCT02681549 · Phase 2 · registry result, not featured evidence 5 mg weekly fatigue 66.7% decreased appetite 55.6% cough 33.3% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 85.7% cough 42.9% hypophosphataemia 42.9% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 77.8% musculoskeletal and connective tissue disorders 55.6% cough 38.9% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 47.4% musculoskeletal and connective tissue disorders 44.7% decreased appetite 35.5% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly nausea 56.6% fatigue 54.7% musculoskeletal and connective tissue disorders 45.3% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 57.9% musculoskeletal and connective tissue disorders 44.7% blood alkaline phosphatase increased 36.8% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 3 mg weekly decreased appetite 50% cough 33.3% diarrhoea 33.3% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 300 mg BID + 200 mg Q3W fatigue 65% nausea 55% vomiting 50% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 50% back pain 38.9% diarrhoea 38.9% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 48.4% nausea 30.1% cough 26.2% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50 mg BID + 200 mg Q3W fatigue 65% arthralgia 45% nausea 45% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 25 mg BID + 200 mg Q3W arthralgia 100% constipation 75% cough 75% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination dyspnea 90% fatigue 90% pain 70% NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination fatigue 100% cough 80% pain 60% NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination 30 Gy over 5 fractions headache 33.3% agitation 16.7% dermatitis, other 16.7% NCT02858869 · Phase 1 · registry result, not featured evidence · combination 27 Gy over 3 fractions symptomatic radionecrosis 16.7% constipation 8.3% dermatitis, other 8.3% NCT02858869 · Phase 1 · registry result, not featured evidence · combination 18-21 Gy in one fraction symptomatic radionecrosis 14.3% agitation 0% constipation 0% NCT02858869 · Phase 1 · registry result, not featured evidence · combination 3.2/4 mg anaemia 80% decreased appetite 80% fatigue 80% NCT02009449 · Phase 1 · registry result, not featured evidence 3.2/4 mg fatigue 100% anaemia 80% headache 60% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 1.6/2 mg anaemia 75.2% fatigue 59% thrombocytopenia 59% NCT02009449 · Phase 1 · registry result, not featured evidence 1.6/2 mg fatigue 85.3% anaemia 76.5% thrombocytopenia 58.8% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 1.6/2 mg anaemia 68.4% fatigue 59.6% cough 42.1% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% constipation 66.7% decreased appetite 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence 0.8/1 mg fatigue 88.9% nausea 83.3% anaemia 77.8% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% thrombocytopenia 66.7% fatigue 50% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% fatigue 66.7% thrombocytopenia 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg fatigue 100% decreased appetite 66.7% lipase increased 50% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg fatigue 85.7% thrombocytopenia 71.4% anaemia 57.1% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg activated partial thromboplastin time prolonged 100% alanine aminotransferase increased 100% anaemia 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 100% fatigue 100% thrombocytopenia 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg anaemia 83.3% fatigue 83.3% nausea 83.3% NCT02009449 · Phase 1 · registry result, not featured evidence 0.4/0.5 mg anaemia 100% dyspnoea 66.7% fatigue 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg thrombocytopenia 100% fatigue 66.7% anaemia 33.3% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg fatigue 100% anaemia 80% hypokalaemia 60% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.2/0.25 mg anaemia 50% fatigue 50% injection site erythema 50% NCT02009449 · Phase 1 · registry result, not featured evidence 0.2/0.25 mg asthenia 100% neutropenia 100% spermatic cord disorder 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.08/0.1 mg injection site erythema 75% abdominal distension 50% abdominal pain 50% NCT02009449 · Phase 1 · registry result, not featured evidence 280 mg PO BID aspartate aminotransferase increased 14.3% cough 14.3% fatigue 14.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg / 280 mg anemia 66.7% back pain 66.7% diarrhea 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO BID lipase increased 66.7% alkaline phosphatase increased 33.3% anorexia 33.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO daily hepatobiliary disorders - other, specify 100% abdominal pain 66.7% back pain 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 20 mg/kg hypertension 28.6% anemia 14.3% arthralgia 14.3% NCT03236935 · Phase 1 · registry result, not featured evidence 10 mg/kg Q2W fatigue 58.9% diarrhoea 38.9% nausea 38.3% NCT01295827 · Phase 1 · registry result, not featured evidence 10 mg/kg Q3W fatigue 52.1% diarrhoea 35.5% nausea 34.5% NCT01295827 · Phase 1 · registry result, not featured evidence · combination 10 mg/kg Q2W fatigue 38.6% decreased appetite 27.2% dyspnoea 25.7% NCT01295827 · Phase 1 · registry result, not featured evidence 10 mg/kg Q3W fatigue 42.5% decreased appetite 30.7% cough 30% NCT01295827 · Phase 1 · registry result, not featured evidence · combination 10 mg/kg Q2W fatigue 50% decreased appetite 30% constipation 20% NCT01295827 · Phase 1 · registry result, not featured evidence · combination 3 mg/kg Q2W back pain 66.7% nausea 66.7% breast pain 33.3% NCT01295827 · Phase 1 · registry result, not featured evidence 2 mg/kg Q3W fatigue 47.5% nausea 34.6% diarrhoea 33.3% NCT01295827 · Phase 1 · registry result, not featured evidence · combination 2 mg/kg Q3W fatigue 27.9% diarrhoea 19.7% constipation 16.4% NCT01295827 · Phase 1 · registry result, not featured evidence 1 mg/kg Q2W pruritus 75% abdominal pain upper 25% anaemia 25% NCT01295827 · Phase 1 · registry result, not featured evidence bradycardia 25% diarrhoea 25% fatigue 25% NCT01295827 · Phase 1 · registry result, not featured evidence diarrhoea 66.7% fatigue 66.7% pruritus 66.7% NCT01295827 · Phase 1 · registry result, not featured evidence decreased appetite 66.7% fatigue 50% depression 33.3% NCT01295827 · Phase 1 · registry result, not featured evidence |
Colorectal Cancer
Shared mechanism: PD-1 · full Colorectal Cancer pipeline
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Pembrolizumab
Marketed by Merck & Co.
NCT02460198 · Phase 2 · completed
The study treated 124 participants with pembrolizumab in a non-randomized, open-label, single-group design without a placebo or active comparator. Although the primary endpoint was an objective tumor response measure assessed by central imaging, the study had no formal between-group comparison and therefore provides limited evidence of pembrolizumab’s comparative benefit.
Next expected readout: December 2026 · NCT05784688 (registry estimate)
Reported efficacy
Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48) (not_applicable)
Result source: NCT02460198
Results for Colorectal Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opdivo Qvantig: no structured comparison results are available for Colorectal Cancer.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pembrolizumab
show 7 more results
show 17 more results
show 19 more results
show 22 more results
show 7 more results
show 7 more results
show 5 more results
show 10 more results
show 10 more results
show 7 more results
show 7 more results
show 7 more results
+ 6 further endpoints in the CSV export.
Available safety results
Pembrolizumab
| Dropout rate | n/a: no completion milestoneCohort A: Triple Negative Breast C NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 44 more resultsn/a: no completion milestoneCohort B: Ovarian Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort C: Gastric Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort D1: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort D2: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneCohort E: Glioblastoma Multiforma NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort F: Biliary Tract Cancer (Le NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort G: Pancreatic Cancer (Lenva NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg + 200 mg NCT03473925 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone30 mg + 200 mg NCT03473925 · Phase 2 · registry result, not featured evidence · combination 100%1200 ug/kg NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 100%960 ug/kg NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 66.7%480 ug/kg NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm I NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm II NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm III NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm IV NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm IVa NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm V NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm Va NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Biomarker Cohort NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 0%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 0%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 66.7%3 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 57.1%1400 mg + 200 mg NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination 87.5%1100 mg + 200 mg NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination 73.8%Part 2, Group 1: CRC MMR-proficien NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination 93.5%Part 2, Group 2: Pancreatic Cancer NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination 75%Part 2, Group 3: NSCLC PD-L1 Low, NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination 73.7%Part 2, Group 4a: Refractory / Rel NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination 66.7%Part 2, Group 4b: Refractory/Relap NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | —Cohort A: Triple Negative Breast C NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 44 more results—Cohort B: Ovarian Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Gastric Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort D1: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort D2: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence —Cohort E: Glioblastoma Multiforma NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort F: Biliary Tract Cancer (Le NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort G: Pancreatic Cancer (Lenva NCT03797326 · Phase 2 · registry result, not featured evidence · combination —100 mg + 200 mg NCT03473925 · Phase 2 · registry result, not featured evidence · combination —30 mg + 200 mg NCT03473925 · Phase 2 · registry result, not featured evidence · combination —1200 ug/kg NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —960 ug/kg NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —480 ug/kg NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm I NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm II NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm III NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm IV NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm IVa NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm V NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm Va NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Biomarker Cohort NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —3 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —1400 mg + 200 mg NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —1100 mg + 200 mg NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 1: CRC MMR-proficien NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 2: Pancreatic Cancer NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 3: NSCLC PD-L1 Low, NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 4a: Refractory / Rel NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 4b: Refractory/Relap NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination 1.6%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 51.6%Cohort A: Triple Negative Breast C NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 44 more results61.3%Cohort B: Ovarian Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination 57.6%Cohort C: Gastric Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination 52.4%Cohort D1: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence · combination 40%Cohort D2: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence 29.7%Cohort E: Glioblastoma Multiforma NCT03797326 · Phase 2 · registry result, not featured evidence · combination 60.8%Cohort F: Biliary Tract Cancer (Le NCT03797326 · Phase 2 · registry result, not featured evidence · combination 47.6%Cohort G: Pancreatic Cancer (Lenva NCT03797326 · Phase 2 · registry result, not featured evidence · combination 27.8%100 mg + 200 mg NCT03473925 · Phase 2 · registry result, not featured evidence · combination 33.3%30 mg + 200 mg NCT03473925 · Phase 2 · registry result, not featured evidence · combination 16.7%1200 ug/kg NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 33.3%960 ug/kg NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 66.7%480 ug/kg NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 25%Phase 2a: Arm I NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 82.4%Phase 2a: Arm II NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 64.7%Phase 2a: Arm III NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 51.7%Phase 2a: Arm IV NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 71.4%Phase 2a: Arm IVa NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 56.3%Phase 2a: Arm V NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 79.4%Phase 2a: Arm Va NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 69.2%Phase 2a: Biomarker Cohort NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 22.2%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 57.1%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 55.6%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 43.4%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 45.3%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 36.8%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 66.7%3 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 45%300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 51%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 40%50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —1400 mg + 200 mg NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —1100 mg + 200 mg NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 1: CRC MMR-proficien NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 2: Pancreatic Cancer NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 3: NSCLC PD-L1 Low, NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 4a: Refractory / Rel NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 4b: Refractory/Relap NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination 38.2%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 35.7%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 37.5%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | hypertension 51.6% diarrhoea 45.2% hypothyroidism 45.2% NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 35 more resultshypertension 67.7% diarrhoea 61.3% decreased appetite 48.4% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 37.4% nausea 31.3% asthenia 30.3% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 56.2% diarrhoea 44.8% decreased appetite 43.8% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 56.7% diarrhoea 53.3% dysphonia 40% NCT03797326 · Phase 2 · registry result, not featured evidence hypertension 50.5% asthenia 28.7% hypothyroidism 27.7% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 56.9% diarrhoea 41.2% fatigue 39.2% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 53.4% nausea 35.9% decreased appetite 32% NCT03797326 · Phase 2 · registry result, not featured evidence · combination 100 mg + 200 mg nausea 29.6% fatigue 25.9% pyrexia 22.2% NCT03473925 · Phase 2 · registry result, not featured evidence · combination 30 mg + 200 mg fatigue 33.3% decreased appetite 27.5% pyrexia 23.5% NCT03473925 · Phase 2 · registry result, not featured evidence · combination 1200 ug/kg chills 83.3% fatigue 66.7% injection site erythema 66.7% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 960 ug/kg oedema peripheral 66.7% anaemia 33.3% blood bilirubin increased 33.3% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 480 ug/kg headache 100% pyrexia 100% chills 66.7% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination alanine aminotransferase increased 31.3% cough 31.3% oedema peripheral 31.3% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination fatigue 41.2% nausea 29.4% oedema peripheral 23.5% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination fatigue 47.1% decreased appetite 35.3% pruritus 23.5% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination nausea 48.3% fatigue 44.8% pyrexia 41.4% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination fatigue 42.9% pyrexia 42.9% decreased appetite 35.7% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination pyrexia 43.8% fatigue 37.5% nausea 31.3% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination fatigue 47.1% anaemia 32.4% decreased appetite 26.5% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination aspartate aminotransferase increased 38.5% anaemia 30.8% fatigue 30.8% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 66.7% decreased appetite 55.6% cough 33.3% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 85.7% cough 42.9% hypophosphataemia 42.9% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 77.8% musculoskeletal and connective tissue disorders 55.6% cough 38.9% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 47.4% musculoskeletal and connective tissue disorders 44.7% decreased appetite 35.5% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly nausea 56.6% fatigue 54.7% musculoskeletal and connective tissue disorders 45.3% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 57.9% musculoskeletal and connective tissue disorders 44.7% blood alkaline phosphatase increased 36.8% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 3 mg weekly decreased appetite 50% cough 33.3% diarrhoea 33.3% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 300 mg BID + 200 mg Q3W fatigue 65% nausea 55% vomiting 50% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 50% back pain 38.9% diarrhoea 38.9% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 48.4% nausea 30.1% cough 26.2% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50 mg BID + 200 mg Q3W fatigue 65% arthralgia 45% nausea 45% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 25 mg BID + 200 mg Q3W arthralgia 100% constipation 75% cough 75% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg diarrhoea 25.2% constipation 23.6% fatigue 23.6% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 75 mg aspartate aminotransferase increased 21.4% back pain 21.4% fatigue 21.4% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 50 mg fatigue 37.5% diarrhoea 25% decreased appetite 18.8% NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
Head and Neck Squamous Cell Carcinoma
Shared mechanism: PD-1 · full Head and Neck Squamous Cell Carcinoma pipeline
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Pembrolizumab
Marketed by Merck & Co.
NCT02358031 · Phase 3 · completed
KEYNOTE-048 was a randomized, open-label, active-controlled Phase 3 in 882 patients with recurrent or metastatic HNSCC. Its primary endpoint, overall survival, is a clinical outcome and was met at a pre-specified interim analysis. An open-label trial is never graded strong under the rubric.
Next expected readout: November 2026 · NCT02955290 (registry estimate)
Reported efficacy
Pembro Combo vs Control: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in All Participants (Up to approximately 47 months); Pembro Combo vs Control: PFS Per RECIST 1.1 by BICR in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 (Up to approximately 47 months); Pembro Combo vs Control: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥20 (Up to approximately 47 months); Pembro Combo vs Control: Overall Survival (OS) in All Participants (Up to approximately 47 months); Pembro Combo vs Control: OS in Participants With PD-L1 CPS ≥1 (Up to approximately 47 months); Pembro Combo vs Control: OS in Participants With PD-L1 CPS ≥20 (Up to approximately 47 months); Pembro Mono vs Control: PFS Per RECIST 1.1 by BICR in All Participants (Up to approximately 47 months); Pembro Mono vs Control: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1 (Up to approximately 47 months); Pembro Mono vs Control: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥20 (Up to approximately 47 months); Pembro Mono vs Control: OS in All Participants (Up to approximately 47 months); Pembro Mono vs Control: OS in Participants With PD-L1 CPS ≥1 (Up to approximately 47 months); Pembro Mono vs Control: OS in Participants With PD-L1 CPS ≥20 (Up to approximately 47 months): Primary endpoint, overall survival at a pre-specified interim analysis: pembrolizumab plus platinum/fluorouracil vs cetuximab plus platinum/fluorouracil, median 13.0 vs 10.7 months, HR 0.77; pembrolizumab alone vs cetuximab-chemotherapy in PD-L1 CPS >=1, HR 0.65 (95% CI 0.53 to 0.80) (KEYTRUDA label, KEYNOTE-048). (met)
Result source: NCT02358031
Results for Head and Neck Squamous Cell Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opdivo Qvantig: no structured comparison results are available for Head and Neck Squamous Cell Carcinoma.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pembrolizumab
show 32 more results
show 9 more results
show 6 more results
show 3 more results
show 3 more results
show 3 more results
Available safety results
Pembrolizumab
| Dropout rate | n/a: no completion milestone300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 28 more resultsn/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —5.0 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone5.0 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —3.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone3.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —1.6 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1.6 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.8 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone0.8 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.4 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone0.4 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.2 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 57.1%20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | —300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 28 more results—100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —5.0 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —5.0 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —3.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —3.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —1.6 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —1.6 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.8 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.8 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.4 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.4 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.2 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 1.6%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 45%300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 28 more results50%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 51%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 40%50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50%5.0 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —5.0 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0%3.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —3.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 42.9%2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 33.3%1.6 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —1.6 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 75%0.8 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.8 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 50%0.4 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.4 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0%0.2 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 14.3%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 66.7%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 100%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 38.2%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 35.7%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 37.5%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 14.3%20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 300 mg BID + 200 mg Q3W fatigue 65% nausea 55% vomiting 50% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 19 more results100 mg BID + 200 mg Q3W fatigue 50% back pain 38.9% diarrhoea 38.9% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 48.4% nausea 30.1% cough 26.2% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50 mg BID + 200 mg Q3W fatigue 65% arthralgia 45% nausea 45% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 25 mg BID + 200 mg Q3W arthralgia 100% constipation 75% cough 75% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 5.0 mg pain in extremity 50% anaemia 33.3% arthralgia 33.3% NCT04879849 · Phase 1 · registry result, not featured evidence · combination 3.5 mg diarrhoea 50% fatigue 50% chills 33.3% NCT04879849 · Phase 1 · registry result, not featured evidence · combination 2.5 mg fatigue 71.4% constipation 57.1% cough 42.9% NCT04879849 · Phase 1 · registry result, not featured evidence · combination 1.6 mg constipation 33.3% device malfunction 33.3% fatigue 33.3% NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0.8 mg fatigue 75% abdominal distension 25% abdominal pain 25% NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0.4 mg anaemia 50% balance disorder 50% constipation 50% NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0.2 mg cough 50% oesophagitis 50% arthralgia 25% NCT04879849 · Phase 1 · registry result, not featured evidence · combination 280 mg PO BID aspartate aminotransferase increased 14.3% cough 14.3% fatigue 14.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg / 280 mg anemia 66.7% back pain 66.7% diarrhea 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO BID lipase increased 66.7% alkaline phosphatase increased 33.3% anorexia 33.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO daily hepatobiliary disorders - other, specify 100% abdominal pain 66.7% back pain 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 100 mg diarrhoea 25.2% constipation 23.6% fatigue 23.6% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 75 mg aspartate aminotransferase increased 21.4% back pain 21.4% fatigue 21.4% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 50 mg fatigue 37.5% diarrhoea 25% decreased appetite 18.8% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 20 mg/kg hypertension 28.6% anemia 14.3% arthralgia 14.3% NCT03236935 · Phase 1 · registry result, not featured evidence |
Renal Cell Carcinoma
Shared mechanism: PD-1 · full Renal Cell Carcinoma pipeline
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Pembrolizumab
Marketed by Merck & Co.
NCT02853331 · Phase 3 · completed
The trial randomly assigned 861 participants to open-label pembrolizumab plus axitinib or active-controlled sunitinib monotherapy, with progression assessed by blinded independent central imaging review. Both prespecified primary endpoints favored the combination: progression-free survival was significantly improved (HR 0.69, p=0.00012) and overall survival was significantly improved (HR 0.53, p=0.00005), but the open-label design limits the evidence strength.
Next expected readout: December 2026 · NCT05319015 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) by Independent Imaging Review (IIR) (From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)): Progression-free Survival (PFS) by Independent Imaging Review (IIR) (From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)): Lenvatinib 18 mg Plus Everolimus 5 mg 14.7 months (95% CI 11.1 to 16.7) | Lenvatinib 20 mg Plus Pembrolizumab 200 mg 23.9 months (95% CI 20.8 to 27.7) | Sunitinib 50 mg 9.2 months (95% CI 6 to 11) (met)
Result source: NCT02811861
Results for Renal Cell Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opdivo Qvantig: registry results are on file for Renal Cell Carcinoma, but their comparison mappings are not yet available.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pembrolizumab
show 19 more results
show 4 more results
show 3 more results
show 3 more results
show 2 more results
show 3 more results
Available safety results
Pembrolizumab
| Dropout rate | n/a: no completion milestone300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 35 more resultsn/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 99.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 96.5%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 85.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 0%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | —300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 35 more results—100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence —3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence —280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 1.6%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 45%300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 35 more results50%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 51%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 40%50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 40%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence 60%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 51.3%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence 47.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 56.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 55.6%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 66.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 66.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 16.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 57.1%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 20%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 40%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence 0%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 75%0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 14.3%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 66.7%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 100%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 38.2%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 35.7%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 37.5%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 300 mg BID + 200 mg Q3W fatigue 65% nausea 55% vomiting 50% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 31 more results100 mg BID + 200 mg Q3W fatigue 50% back pain 38.9% diarrhoea 38.9% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 48.4% nausea 30.1% cough 26.2% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50 mg BID + 200 mg Q3W fatigue 65% arthralgia 45% nausea 45% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 25 mg BID + 200 mg Q3W arthralgia 100% constipation 75% cough 75% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 3.2/4 mg anaemia 80% decreased appetite 80% fatigue 80% NCT02009449 · Phase 1 · registry result, not featured evidence 3.2/4 mg fatigue 100% anaemia 80% headache 60% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 1.6/2 mg anaemia 75.2% fatigue 59% thrombocytopenia 59% NCT02009449 · Phase 1 · registry result, not featured evidence 1.6/2 mg fatigue 85.3% anaemia 76.5% thrombocytopenia 58.8% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 1.6/2 mg anaemia 68.4% fatigue 59.6% cough 42.1% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% constipation 66.7% decreased appetite 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence 0.8/1 mg fatigue 88.9% nausea 83.3% anaemia 77.8% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% thrombocytopenia 66.7% fatigue 50% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% fatigue 66.7% thrombocytopenia 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg fatigue 100% decreased appetite 66.7% lipase increased 50% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg fatigue 85.7% thrombocytopenia 71.4% anaemia 57.1% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg activated partial thromboplastin time prolonged 100% alanine aminotransferase increased 100% anaemia 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 100% fatigue 100% thrombocytopenia 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg anaemia 83.3% fatigue 83.3% nausea 83.3% NCT02009449 · Phase 1 · registry result, not featured evidence 0.4/0.5 mg anaemia 100% dyspnoea 66.7% fatigue 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg thrombocytopenia 100% fatigue 66.7% anaemia 33.3% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg fatigue 100% anaemia 80% hypokalaemia 60% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.2/0.25 mg anaemia 50% fatigue 50% injection site erythema 50% NCT02009449 · Phase 1 · registry result, not featured evidence 0.2/0.25 mg asthenia 100% neutropenia 100% spermatic cord disorder 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.08/0.1 mg injection site erythema 75% abdominal distension 50% abdominal pain 50% NCT02009449 · Phase 1 · registry result, not featured evidence 280 mg PO BID aspartate aminotransferase increased 14.3% cough 14.3% fatigue 14.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg / 280 mg anemia 66.7% back pain 66.7% diarrhea 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO BID lipase increased 66.7% alkaline phosphatase increased 33.3% anorexia 33.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO daily hepatobiliary disorders - other, specify 100% abdominal pain 66.7% back pain 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 100 mg diarrhoea 25.2% constipation 23.6% fatigue 23.6% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 75 mg aspartate aminotransferase increased 21.4% back pain 21.4% fatigue 21.4% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 50 mg fatigue 37.5% diarrhoea 25% decreased appetite 18.8% NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
Metastatic Colorectal Cancer
Shared mechanism: PD-1 · full Metastatic Colorectal Cancer pipeline
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Pembrolizumab
Marketed by Merck & Co.
NCT02460198 · Phase 2 · completed
The study treated 124 participants with pembrolizumab in a non-randomized, open-label, single-group design without a placebo or active comparator. Although the primary endpoint was an objective tumor response measure assessed by central imaging, the study had no formal between-group comparison and therefore provides limited evidence of pembrolizumab’s comparative benefit.
Next expected readout: December 2026 · NCT04140526 (registry estimate)
Reported efficacy
Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48) (not_applicable)
Result source: NCT02460198
Results for Metastatic Colorectal Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opdivo Qvantig: no structured comparison results are available for Metastatic Colorectal Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Esophageal Squamous Cell Carcinoma
Shared mechanism: PD-1 · full Esophageal Squamous Cell Carcinoma pipeline
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Pembrolizumab
Marketed by Merck & Co.
NCT03189719 · Phase 3 · completed
KEYNOTE-590 was a randomized, double-blind, placebo-controlled Phase 3 in 749 patients with advanced esophageal or gastroesophageal junction carcinoma. Its primary endpoints, overall and progression-free survival, are clinical outcomes and were met. The benefit was concentrated in PD-L1 CPS >=1 tumours, and the sources read give no power calculation, so the grade is moderate.
Next expected readout: December 2026 · NCT06907602 (registry estimate)
Reported efficacy
Overall Survival (OS) in Participants With Esophageal Squamous Cell Carcinoma (ESCC) Whose Tumors Are Programmed Cell Death-Ligand 1 (PD-L1) Biomarker-Positive (Combined Positive Score [CPS] ≥10) (Up to approximately 34 months); OS in Participants With ESCC (Up to approximately 34 months); OS in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10) (Up to approximately 34 months); OS in All Participants (Up to approximately 34 months); Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) As Assessed By Investigator in Participants With ESCC (Up to approximately 34 months); PFS Per RECIST 1.1 As Assessed By Investigator in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10) (Up to approximately 34 months); PFS Per RECIST 1.1 As Assessed By Investigator in All Participants (Up to approximately 34 months): Primary endpoints, overall survival and progression-free survival: pembrolizumab plus cisplatin/fluorouracil improved both vs placebo plus chemotherapy; the label restricts use to PD-L1 CPS >=1, as an exploratory CPS <1 analysis showed OS HR 0.96 (KEYTRUDA label, KEYNOTE-590). (met)
Result source: NCT03189719
Results for Esophageal Squamous Cell Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opdivo Qvantig: no structured comparison results are available for Esophageal Squamous Cell Carcinoma.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Opdivo Qvantig's landscape · Pembrolizumab's landscape